We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for camizestrant (AstraZeneca Pty Ltd)
Active ingredients
camizestrant
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Camizestrant in combination with a CDK4/6 inhibitor is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during first line endocrine-based therapy
Therapeutic area
Oncology